Oslo, April 15, 2024: In connection with the Annual General Meeting of
Ultimovacs ASA to be held on April 18, 2024, Jónas Einarsson, Chair of the Board
of Directors, has so far received proxy based voting rights without voting
instructions for 9,063,854 shares, representing 26.34% of the total voting
rights in the company.
The proxies are only valid for the Annual General Meeting on April 18, 2024.
This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
For further information, please see www.ultimovacs.com
(http://www.ultimovacs.com) or contact:
Jónas Einarsson, Chair of the Board of Directors of Ultimovacs ASA
Email: je@radforsk.no
Phone: +47 480 96 355
Carlos de Sousa, CEO
Email: carlos.desousa@ultimovacs.com
Phone: +47 908 92507
Anne Worsøe, Head of IR & Communication
Email: anne.worsoe@ultimovacs.com
Phone: +47 906 86815